153 related articles for article (PubMed ID: 28538090)
1. Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants.
Armstrong AE; Danner-Koptik K; Golden S; Schneiderman J; Kletzel M; Reichek J; Gosiengfiao Y
J Pediatr Hematol Oncol; 2018 Jan; 40(1):31-35. PubMed ID: 28538090
[TBL] [Abstract][Full Text] [Related]
2. Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience.
Zaky W; Dhall G; Ji L; Haley K; Allen J; Atlas M; Bertolone S; Cornelius A; Gardner S; Patel R; Pradhan K; Shen V; Thompson S; Torkildson J; Sposto R; Finlay JL
Pediatr Blood Cancer; 2014 Jan; 61(1):95-101. PubMed ID: 23934933
[TBL] [Abstract][Full Text] [Related]
3. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study.
Kletzel M; Katzenstein HM; Haut PR; Yu AL; Morgan E; Reynolds M; Geissler G; Marymount MH; Liu D; Kalapurakal JA; Shore RM; Bardo DM; Schmoldt J; Rademaker AW; Cohn SL
J Clin Oncol; 2002 May; 20(9):2284-92. PubMed ID: 11980999
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Tushabe DA; Berthold F
Cochrane Database Syst Rev; 2015 Jan; 1():CD010685. PubMed ID: 25634649
[TBL] [Abstract][Full Text] [Related]
5. Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue.
Elzembely MM; Dahlberg AE; Pinto N; Leger KJ; Chow EJ; Park JR; Carpenter PA; Baker KS
Pediatr Blood Cancer; 2019 Jan; 66(1):e27421. PubMed ID: 30151986
[TBL] [Abstract][Full Text] [Related]
6. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants.
Marcus KJ; Shamberger R; Litman H; von Allmen D; Grupp SA; Nancarrow CM; Goldwein J; Grier HE; Diller L
J Pediatr Hematol Oncol; 2003 Dec; 25(12):934-40. PubMed ID: 14663275
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
8. Long-term adverse effects on dentition in children with poor-risk neuroblastoma treated with high-dose chemotherapy and autologous stem cell transplantation with or without total body irradiation.
Hölttä P; Alaluusua S; Saarinen-Pihkala UM; Wolf J; Nyström M; Hovi L
Bone Marrow Transplant; 2002 Jan; 29(2):121-7. PubMed ID: 11850706
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
[TBL] [Abstract][Full Text] [Related]
10. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study.
Sung KW; Son MH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ; Lee SK; Choi YS; Lim DH; Kim JS; Kim DW
Bone Marrow Transplant; 2013 Jan; 48(1):68-73. PubMed ID: 22635247
[TBL] [Abstract][Full Text] [Related]
11. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.
Saarinen-Pihkala UM; Hovi L; Koivusalo A; Jahnukainen K; Karikoski R; Sariola H; Wikström S
Pediatr Blood Cancer; 2012 Dec; 59(7):1190-7. PubMed ID: 22492714
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
13. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
George RE; Li S; Medeiros-Nancarrow C; Neuberg D; Marcus K; Shamberger RC; Pulsipher M; Grupp SA; Diller L
J Clin Oncol; 2006 Jun; 24(18):2891-6. PubMed ID: 16782928
[TBL] [Abstract][Full Text] [Related]
14. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.
Berthold F; Ernst A; Hero B; Klingebiel T; Kremens B; Schilling FH; Simon T
Br J Cancer; 2018 Aug; 119(3):282-290. PubMed ID: 29991700
[TBL] [Abstract][Full Text] [Related]
16. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
17. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma.
Martin A; Schneiderman J; Helenowski IB; Morgan E; Dilley K; Danner-Koptik K; Hatahet M; Shimada H; Cohn SL; Kletzel M; Hijiya N
Pediatr Blood Cancer; 2014 Aug; 61(8):1350-6. PubMed ID: 24634399
[TBL] [Abstract][Full Text] [Related]
18. Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
Talleur AC; Triplett BM; Federico S; Mamcarz E; Janssen W; Wu J; Shook D; Leung W; Furman WL
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1910-1917. PubMed ID: 28733263
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
20. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma.
Hobbie WL; Moshang T; Carlson CA; Goldmuntz E; Sacks N; Goldfarb SB; Grupp SA; Ginsberg JP
Pediatr Blood Cancer; 2008 Nov; 51(5):679-83. PubMed ID: 18623215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
